Proteogenomics of clear cell renal cell carcinoma response to tyrosine kinase inhibitor

The tyrosine kinase inhibitor (TKI) Sunitinib is one the therapies approved for advanced renal cell carcinoma. Here, we undertake proteogenomic profiling of 115 tumors from patients with clear cell renal cell carcinoma (ccRCC) undergoing Sunitinib treatment and reveal the molecular basis of differen...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Hailiang, Bai, Lin, Wu, Xin-Qiang, Tian, Xi, Feng, Jinwen, Wu, Xiaohui, Shi, Guo-Hai, Pei, Xiaoru, Lyu, Jiacheng, Yang, Guojian, Liu, Yang, Xu, Wenhao, Anwaier, Aihetaimujiang, Zhu, Yu, Cao, Da-Long, Xu, Fujiang, Wang, Yue, Gan, Hua-Lei, Sun, Meng-Hong, Zhao, Jian-Yuan, Qu, Yuanyuan, Ye, Dingwei, Ding, Chen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10352361/
https://www.ncbi.nlm.nih.gov/pubmed/37460463
http://dx.doi.org/10.1038/s41467-023-39981-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10352361/
https://www.ncbi.nlm.nih.gov/pubmed/37460463
http://dx.doi.org/10.1038/s41467-023-39981-6

Ejemplares similares